Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Peter M. A. Calverley (Liverpool, United Kingdom), Peter M.A. Calverley, Emiel F.M. Wouters, Helen Finnigan, Kay Tetzlaff, Helgo Magnussen. Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD. Eur Respir J 2016; 48: Suppl. 60, 4067

Member's Comments

No comment yet.

Related content which might interest you: Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Relationship of blood eosinophil count to exacerbations in COPD Source: International Congress 2016 – Airway response to infection Year: 2016 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<% Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Characterization of readmissions in patients hospitalized with COPD exacerbation Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Mukoregulatory drugs in treating COPD Source: International Congress 2014 – Predictors Year: 2014 BNP level in patients with COPD exacerbations Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Risk factors for another hospitalization in COPD patients hospitalized for exacerbation Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Association of COPD inhaled  medication adherence with hospitalization for acute exacerbation of COPD (AECOPD) Source: International Congress 2017 – COPD management Year: 2017 Impact of frequent exacerbations in patients with COPD Source: International Congress 2014 – Clinical presentations Year: 2014 A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 Assessment of malondialdehyde in the airways during treatment of COPD exacerbations Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 Importance of the initial behaviour of patients in avoiding late recovery from COPD exacerbations Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013